RFA-DK-23-021: Cardiovascular Repository Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Allowed).
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $600,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on April 11, 2024.
From the official notice on Grants.gov, last changed November 30, 2023. Checked November 7, 2026.
- Award ceiling$600,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeT1D / U01
- Clinical trialsNot allowed
- Funded byNIDDK
- Median yearly award$1.0 million
- Typical project length3 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-DK-23-021 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-23-021 in the NIH Guide.
Key dates
| Posted | November 30, 2023 |
|---|---|
| Deadline | April 11, 2024 |
| Archived by Grants.gov | May 17, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $1.0 million; it allows up to $600,000 per award.
- Most of the money in the 4 programs behind this notice (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Cardiovascular complications are the leading cause of death for individuals with type 1 diabetes (T1D) and significantly shorten their lives. Cardiovascular disease (CVD) progression in people with T1D differs from that observed in people with type 2 diabetes (T2D) and residual increased risk of CVD remains after treatment of standard risk factors, such as hyperglycemia, hypertension, and hyperlipidemia. The NIH Cardiovascular Repository for T1D (CaRe-T1D) was initiated with the goal of establishing a biorepository of human CV tissue and a scientific consortium to advance and support discovery and mechanistic research that increase the understanding of CVD in T1D. The first phase launched the biorepository and now in the second phase investigative teams will be added to form a consortium with the biorepository serving as the Coordinating Center (CC). CaRe-T1D is currently collecting hearts, kidneys, carotid and peripheral arteries, and blood from organ donors with T1D, T2D and without diabetes. The goal of this NOFO is to attract investigative teams with complementary interests and expertise who will leverage these resources through individual and collaborative studies to advance our knowledge of the pathogenesis of CVD in T1D.
Funded under RFA-DK-23-021 so far
NIH funded 6 projects under RFA-DK-23-021 in fiscal 2024 to 2026, at 6 institutions. The median yearly award was $1.0 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Discovery and therapeutic targeting non-coding RNAs in T1D- or T2D-associated atherosclerosis | Brigham and Women's Hospital | 2026 | $1.0 million |
| Single-cell, multi-omic investigation of epicardial adipose and coronary endothelial dysfunction in type 1 diabetes | University of California, San Diego | 2026 | $991,069 |
| Immunometabolism and the Cardio-Renal Axis in T1D-associated Atherosclerosis: Insights from the CaRe T1D Biobank | University of Washington | 2026 | $1.0 million |
| Molecular Drivers of Atherosclerosis in Diabetes | University of Virginia | 2026 | $947,600 |
| Characterization of risk factors for excessive cardiovascular diseases (CVD) from circulating and cardiovascular tissues of people with well-controlled chronic type 1 diabetes | Joslin Diabetes Center | 2026 | $849,124 |
| Substance P Metabolites and Receptors in the Pathogenesis of Cardiac Disease in Type 1 Diabetes | West Virginia University | 2026 | $714,948 |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Who has won Lung Diseases Research grants before
From fiscal 2021 to 2025, Lung Diseases Research (93.838) awarded $8.7 million across 5 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 1 | $5.4 million |
| New England Research Institutes Inc | Massachusetts | 1 | $2.7 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 1 | $355,699 |
| University of Washington | Washington | 1 | $350,272 |
| The Trustees of Columbia University in the City of New York | New York | 1 | $319,659 |
Other programs behind this notice
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-23-021 still open?
No. It closed on April 11, 2024.
Who can apply for Cardiovascular Repository Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Allowed).?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Cardiovascular Repository Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Allowed).?
Closed April 11, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $600,000 each.
Who has been funded under RFA-DK-23-021?
NIH RePORTER lists 6 projects funded under RFA-DK-23-021 in fiscal 2024 to 2026, at 6 institutions. The most were at Brigham and Women's Hospital, University of California, San Diego, University of Washington.
Who has won Cardiovascular Diseases Research grants before?
The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, Regents of the University of Michigan. The program made 11,798 awards worth $15 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)